טוען...
Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings
INTRODUCTION: In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet. CASE PRESENTATION: A 76‐year‐old man was initially referred...
שמור ב:
| הוצא לאור ב: | IJU Case Rep |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7292163/ https://ncbi.nlm.nih.gov/pubmed/32743396 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/iju5.12062 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|